Patient, Manufacturer, and Other Stakeholder Engagement

ICER is committed to a transparent public engagement process to ensure that all stakeholders have the opportunity to provide input to our reports.

More detailed information regarding ICER’s public engagement process may be found below and in these documents:

Our interactive, transparent process starts with Topic Selection.

Once a topic is announced, there are four formal opportunities, outlined below, for patients, manufacturers, and other stakeholders to provide written and/or oral feedback. Written comments from the public are invited at three times during the report preparation process, and there is an additional opportunity for oral comment at the public meeting.

Please note that all submitted comments may be made public.

Public comments allow ICER to address the concerns of patients, clinicians, policymakers, manufacturers, and other health care decision makers and ensure that the report has the broadest possible relevancy. 

1) Give Input on a New Topic

As part of ICER’s Patient Engagement Program, ICER provides early notifications to patient groups from therapeutic areas when it has high certainty that it will pursue an assessment pertaining to their focus. Topics are chosen based on several factors, including input from the public.  Learn more about how we choose topics, or submit a suggestion for a future review.  In this initial outreach, we provide an overview of ICER procedures, answer your questions about ICER, and, if needed, can facilitate connections with other patient leaders who have participated in an ICER review.  For major therapeutic classes (i.e., immunomodulators for which ICER has performed a class review, treatments for multiple sclerosis, etc.), ICER may schedule an annual conference call or meeting to discuss the emerging pipeline of new treatments, seek input on key priorities, and explore opportunities to gather new data on outcomes of care that are important to patients and families.  This early outreach is intended to give patient organizations a chance to familiarize themselves with ICER and our processes ahead of ICER’s final selection of a topic.

Once ICER has selected a new topic for review, we spend five weeks engaging with targeted stakeholders from that therapeutic area prior to announcing our review to the public.  During this five-week period, ICER schedules scoping calls with patient groups to get their initial input on how we should approach our review and to learn about the lived experiences of the patient community. At the end of week five, we publicly announce the topic and post the draft scoping document for public comment.  This provides the stakeholders with whom we’ve already spoken, as well as additional stakeholders, an opportunity to provide public input to inform ICER’s proposed research agenda.

Patients and advocacy organizations may submit their feedback on these topics through ICER’s patient patient input questionnaire or as an email to All submissions must be received by the deadline specified in each review.

You acknowledge that you are not required to provide information to ICER and that you are doing so voluntarily.  Please see our Terms of Use and Conditions and our Privacy Policy to review how we use and disclose information submitted to us.  While we do not plan to publish information that identifies a particular individual, we intend to use the information submitted as part of our drug reviews.  We recognize that submissions sometimes contain specific medical information that might raise concerns about appropriateness of treatment, physical or mental health, and safety.  The use of this site, and information submitted to ICER, should not take the place of professional medical care.  ICER does not diagnose health problems or provide treatment advice.  The completion of this questionnaire does not trigger any patient-provider relationship.  Any information found on this site, or inferred from this survey, should in no way be considered medical advice or a plan for health management.  Anyone seeking or needing immediate medical treatment is advised to contact their health care provider or visit an emergency room.

2) Draft Scoping Document

The draft scoping document details the proposed topic, including the population, interventions, comparators, outcomes, timeframe, and setting(s) of care. The Draft Scoping Document will be posted for public comment for three weeks, during which anyone can comment on the proposed scope to help ensure that the report and meeting are most relevant to the broadest possible audiences.  To submit a public comment on the draft scoping document, members of the public must submit their comments by email to within three weeks of posting. ICER staff may follow up for further clarification and potential consultation. All comments must be submitted following the below formatting specifications: 

  • Times New Roman, 12-point font size
  • Three pages maximum (excluding references and an appendix that may only contain data tables and figures from published evidence or grey literature, but not additional commentary)
  • Word document (no PDFs)
  • Electronic copy only

Written comments, including those submitted by individual patients, will be posted publicly to the ICER website with the Evidence report.

With the Draft Scoping Document, ICER also posts a stakeholder list, which outlines key organizations ICER intends to reach out to throughout the report process to gather insights. Inclusion on this list does not imply the organizations’ endorsement of ICER’s work. Further recommendations from the public for additional stakeholders are welcomed.

3) Draft Evidence Report and Draft Voting Questions

Both documents will be posted to the relevant program’s webpage with an announcement (approximately seven weeks prior to the meeting date), and the public comment period will be open for four weeks. Anyone may comment on the Draft Evidence Report, and ICER will consider incorporating the feedback in an updated Evidence Report that will be posted before the in-person meeting.

Written comments, including those submitted by individual patients, will be posted publicly to the ICER website with the Evidence report and will be distributed to members of the relevant voting body prior to the public meeting.

Members of the public wishing to submit a written public comment on the Draft Evidence Report or voting questions must do so within the four week posting period. Comments must be emailed as an attachment to and must meet the following style requirements:

  • Times New Roman, 12-point font size
  • Five pages maximum (excluding references and an appendix that may only contain data tables and figures from published evidence or grey literature, but not additional commentary)
  • Word document (no PDFs)
  • Electronic copy only

After all public comments have been received, ICER staff will prepare revised versions of the draft report and voting questions. The process of addressing public comments and revising the draft report and voting questions can take up to two weeks. A revised Evidence Report and voting questions are then posted to the ICER website and distributed to the voting panel for review and meeting preparation.

4) Oral Comments at the public meeting

Each public meeting includes time for oral public comments. Those wishing to speak at the meeting must contact ICER via email ( and provide the name, title, and organization of the speaker. The period to submit a request to speak begins when the Draft Evidence Report is posted and ends when the written public comment period on the Draft Evidence Report closes. For specific dates, see the report timeline on the relevant meeting page.

Each manufacturer involved in the review is offered time to speak during the oral public comment period.  For other public comments, since there may be more requests than can be accommodated during the meeting, and to help provide the opportunity for a broad range of stakeholder perspectives to be heard, public comment slots will only be able to confirmed after the deadline for requests has passed. Priority for these additional public comment slots will be given to patients with the condition under study and subject-matter experts from the patient advocacy, clinical, and research communities. All potential speakers are required to complete a conflict of interest form. All disclosures will be made public at the meeting. Comments at the meeting will be limited to five minutes.

Those who wish to make an oral comment can submit a 750 word written summary of their remarks to be included in the appendix of the final report. For questions on this, please reach out the Program Manager listed on the assessment page for your review.